NCT04827537 is a Phase 2, PHASE3 clinical trial of 20-hydroxyecdysone Oral in Giardia Lamblia Infection, sponsored by Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan.

What drugs are being tested in NCT04827537?

Interventions in NCT04827537: 20-hydroxyecdysone Oral, Metronidazole Oral, Placebo Oral.

What condition does NCT04827537 study?

NCT04827537 studies Giardia Lamblia Infection.

Is NCT04827537 still recruiting?

NCT04827537 is currently active, enrolled. Last updated 4 April 2025.

Last reviewed 2025-04-04 · How we verify

NCT04827537

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-protozoal Effect of Steroid Hormone 20-hydroxyecdysone

Active, enrolled Phase 2, PHASE3 Last updated 4 April 2025

What this trial tests

Phase 2, PHASE3 trial testing 20-hydroxyecdysone Oral in Giardia Lamblia Infection in 200 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 January 2021

Primary endpoint
31 December 2026

31 December 2027

Quick facts

Lead sponsor	Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan
Phase	Phase 2, PHASE3
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	200
Start date	1 January 2021
Primary completion	31 December 2026
Estimated completion	31 December 2027
Sites	1 location across Uzbekistan

Drugs / interventions tested

20-hydroxyecdysone Oral — full drug profile →
Metronidazole Oral
Placebo Oral

Conditions studied

Giardia Lamblia Infection — all drugs for Giardia Lamblia Infection →

Sponsor

Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan

Who can join

Adults 18 to 27, male only, with Giardia Lamblia Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

20-hydroxyecdysone is an ecdysteroid hormone found in invertebrates and plants. 20-hydroxyecdysone exhibits a broad range of biological properties in various in vitro and in vivo models, including anabolic, antioxidant, anti-inflammatory, immunomodulatory, anti-obesity and antidiabetic activities, in addition to acting as neuroprotective and hepatoprotective agent. Ecdysteroids are widely used by athletes as dietary supplements to increase strength and muscle mass during resistance training, to reduce fatigue and to ease recovery. Mhashilkar AS et al. (2016) were revealed anti-parasitic activity of 20-hydroxyecdysone against the human filarial parasites. According to recent searches in academic databases and medical search engines (Google, www.google.com; PubMed, www.ncbi.nlm.nih.gov/pubmed; and Medline, www.medline.com), no studies have been conducted to assess the anti-protozoal activity of 20-hydroxyecdysone. The aim of the study is to assess anti-protozoal activity of 20-hydroxyecdysone in water sports athletes with giardiasis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Analysis of <i>Giardia lamblia</i> Nucleolus as Drug Target: A Review.
Gaona-López C, Martínez-Vázquez AV, Villalobos-Rocha JC, Juárez-Rendón KJ, et al · · 2023 · cited 4× · PMID 37631082 · DOI 10.3390/ph16081168

Verify or expand the search:

Other Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan trials

Trials by the same sponsor.

NCT05045391 — Pulmonary Aspergillosis in Tuberculosis Patients · active not recruiting
NCT03443765 — Serum 25(OH) Vitamin D and Total Serum Immunoglobulin E Levels in Patients With Pityriasis Alba · active not recruiting
NCT03623763 — Vitamin D Level Among Athletes in Uzbekistan · suspended
NCT05783544 — Impact of A. Lumbricoides on Pulmonary Aspergillosis Development · NA · unknown
NCT03441893 — Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis · Phase 1, PHASE2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04827537 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan
Last refreshed: 4 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04827537.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing